Development of a prognostic model in patients with metastatic bone lesions to choose surgical treatment: retrospective study

Cover Page

Cite item

Full Text

Abstract

Choosing surgical management for patients with metastatic bone lesions is one of the essential problems of modern oncology. Surgical interventions are aimed at palliative treatment in most patients with metastatic skeletal lesions. However, curative resections with reconstruction and plasty steps may be considered in selected cases of a solitary metastatic lesion. The life expectancy prognosis based on the histological structure of the tumor is a significant and decisive factor in choosing the appropriate surgery.

Aim. To develop a prognostic model for choosing surgical treatment for metastatic bone lesions.

Materials and methods. Treatment analysis of 715 patients with a history of surgery for metastatic bone lesions of various localizations is presented. A total of 780 surgical interventions were performed. Surgeries for the complications of bone metastases were mainly performed on the spine (48.5% of all surgeries), followed by long bones with 247 (35%) surgeries, pelvic bones with 81 (11%) interventions, and the chest wall with 40 (5.5%) surgeries.

Results. The most unfavorable prognostic factors in patients with metastatic bone lesions are the histological type of the primary tumor of the rapid growth group (risk ratio [RR]=5.11), visceral metastases (RR=3.1), Charlson Comorbidity Index over 10 (RR=3.07) and presence of critical laboratory abnormalities (RR=2.91), as they have the highest rates of impact on survival (over 2.9).

Conclusion. The developed 14-point mathematical score of life expectancy prognosis, which includes five oncological and four clinical factors, defines with an accuracy of 91% the risk groups of good (estimated life expectancy over one year), moderate (6 to 12 months), and poor (less than six months) prognosis in patients with metastatic bone lesions.

About the authors

Artem V. Buharov

Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre

Email: artembuharov@mail.ru
ORCID iD: 0000-0002-2976-8895
SPIN-code: 8349-0930

Cand. Sci. (Med.)

Russian Federation, Moscow

Aleksandr A. Kurilchik

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Radiological Centre

Email: aleksandrkurilchik@yandex.ru
ORCID iD: 0000-0003-2615-078X
SPIN-code: 1751-0982

Cand. Sci. (Med.)

Russian Federation, Obninsk

Artem A. Barashev

National Medical Research Centre for Oncology

Email: barikaa@yandex.ru
ORCID iD: 0000-0002-7242-6938
SPIN-code: 4590-5745

Cand. Sci. (Med.)

Russian Federation, Rostov-on-Don

Vitali A. Derzhavin

Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre

Email: osteosa@yandex.ru
ORCID iD: 0000-0002-4385-9048
SPIN-code: 1811-2737

Cand. Sci. (Med.)

Russian Federation, Moscow

Anna V. Yadrina

Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre

Author for correspondence.
Email: anna_16.06@mail.ru
ORCID iD: 0000-0002-7944-3108
SPIN-code: 9058-3922

Cand. Sci. (Med.)

Russian Federation, Moscow

Dmitrii A. Erin

Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre

Email: erindmal@yandex.ru
ORCID iD: 0000-0002-3501-036X
SPIN-code: 1769-2667

Oncologist

Russian Federation, Moscow

Daniil O. Elkhov

Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre

Email: aeon95@yandex.ru
ORCID iD: 0000-0001-5772-4067

Graduate Student

Russian Federation, Moscow

Mamed D. Aliev

National Medical Research Radiological Centre

Email: oncology@inbox.ru
ORCID iD: 0000-0003-2706-4138
SPIN-code: 4651-9135

D. Sci. (Med.), Prof., Acad. RAS

Russian Federation, Moscow

Andrei D. Kaprin

National Medical Research Radiological Centre

Email: Kaprin@mail.ru
ORCID iD: 0000-0001-8784-8415
SPIN-code: 1759-8101

D. Sci. (Med.), Prof., Acad. RAS

Russian Federation, Moscow

References

  1. Бухаров А.В, Алиев М.Д., Державин В.А., Ядрина А.В. Стратегия персонализированного хирургического лечения онкологических больных с метастазами в костях. Онкология. Журнал им. П.А. Герцена. 2020;9(3):61-5 [Bukharov AV, Aliev MD, Derzhavin VA, Yadrina AV. Strategy for personalized surgical treatment of cancer patients with bone metastases. P.A. Herzen Journal of Oncology. 2020;9(3):61-5 (in Russian)]. doi: 10.17116/onkolog2020903161
  2. Bollen L, van der Linden YM, Pondaag W, et al. Prognostic factors associated with survival in patients with symptomatic spinal bone metastases: a retrospective cohort study of 1,043 patients. Neuro Oncol. 2014;16(7):991-8. doi: 10.1093/neuonc/not318
  3. Алиев М.Д. Онкоортопедия вчера, сегодня, завтра. Вестник онкологического общества. 2013;5(598):3-4 [Aliev MD. Reports on current problems of orthopaedics and the-state-of-the-art in the management of bone and soft tissues sarcomas. Vestnik onkologicheskogo obshchestva. 2013;5(598):3-4 (in Russian)].
  4. Guerrieri AN, Montesi M, Sprio S, et al. Innovative Options for Bone Metastasis Treatment: An Extensive Analysis on Biomaterials-Based Strategies for Orthopedic Surgeons. Front Bioeng Biotechnol. 2020;8:589964. doi: 10.3389/fbioe.2020.589964
  5. Wei LY, Kok SH, Lee YC, et al. Prognosis of medication-related osteonecrosis of the jaws in metastatic prostate cancer patients. Oral Dis. 2022;28(1):182-92. doi: 10.1111/odi.13737
  6. Иванов С.А., Клименко А.А., Курильчик А.А., и др. Комбинированное лечение метастаза почечно-клеточного рака в плечевой кости с реконструктивно-пластическим хирургическим этапом. Исследования и практика в медицине. 2014;1(1):80-3 [Ivanov SA, Klimenko AA, Kurilchik AA, et al. Combined treatment of renal cell carcinoma metastasis located in the humerus with reconstructive plastic surgery stage. Research and Practical Medicine Journal. 2014;1(1):80-3 (in Russian)]. doi: 10.17709/2409-2231-2014-1-1-80-83
  7. Janssen SJ, van der Heijden AS, van Dijke M, et al. 2015 Marshall Urist Young Investigator Award: Prognostication in Patients With Long Bone Metastases: Does a Boosting Algorithm Improve Survival Estimates? Clin Orthop Relat Res. 2015;473(10):3112-21. doi: 10.1007/s11999-015-4446-z
  8. Katagiri H, Okada R, Takagi T, et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 2014;3(5):1359-67. doi: 10.1002/cam4.292
  9. Bauer HC. Controversies in the surgical management of skeletal metastases. J Bone Joint Surg Br. 2005;87(5):608-17. doi: 10.1302/0301-620X.87B5.16021
  10. Zhang L, Hou G, Gao M, et al. Novel survival nomograms for patients with lung metastatic clear cell renal cell carcinoma: A population-based study. Medicine (Baltimore). 2020;99(52):e23465. doi: 10.1097/MD.0000000000023465
  11. Li Y, Hu C. Prevalence and prognosis of synchronous distant metastatic tonsil squamous cell carcinomas. Int J Med Sci. 2021;18(2):528-33. doi: 10.7150/ijms.50966
  12. Owari T, Miyake M, Nakai Y, et al. External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy. J Bone Oncol. 2021;26:100344. doi: 10.1016/j.jbo.2020.100344

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Kaplan–Meier survival curves for the three prognostic groups.

Download (60KB)

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies